Loading
VER001 is an experimental tablet form of fulvestrant from VeraMorph, for hormone receptor-positive breast cancer that has spread. It is in laboratory testing.
VER001 is VeraMorph's oral formulation of fulvestrant, made with its DPOD delivery platform, intended for oestrogen receptor-positive metastatic breast cancer. NCI SBIR award 4R44CA306533-02 funds its preclinical validation. No human data have been published.
Fulvestrant binds the oestrogen receptor and causes it to be degraded; VER001 is a formulation intended to deliver it by mouth rather than by injection. Connects to Estrogen receptor (ERα).
1.VER001 acts on Estrogen receptor (ERα), the hormone receptor or the enzyme that makes the hormone.
Country and place are remembered in this browser only. A postcode is sent to OpenStreetMap's Nominatim service to find coordinates when you press the button; nothing else leaves your device.
Query for this drug: (TITLE:"VER001" OR ABSTRACT:"VER001" OR TITLE:"Oral fulvestrant VeraMorph" OR ABSTRACT:"Oral fulvestrant VeraMorph") AND (cancer OR tumor OR tumour OR oncology OR carcinoma OR lymphoma OR leukemia OR leukaemia OR myeloma OR sarcoma OR melanoma OR glioma). Results are unfiltered search hits about VER001, not a curated reading list.
Shares Estrogen receptor (ERα) and the tag pipeline.
Shares Oral SERDs, Estrogen receptor (ERα).
Shares Oral SERDs, Estrogen receptor (ERα).
Shares Oral SERDs, Estrogen receptor (ERα).
Shares Oral SERDs, Estrogen receptor (ERα).
Shares Oral SERDs, Estrogen receptor (ERα).
Every source this page cites, grouped by who published it. Grouping is read from the web address, not assigned by hand.
A source that has moved or gone is reported by the weekly link check. /audit/